HRouge Profile picture
Weighing machine

Nov 26, 2018, 10 tweets

This is a little bit of a stretch but bear with me. One for fans of #BVXP, #HZD, #ABCAM and perhaps even Phil Fisher.

First, keep in mind these words from the #BVXP Bioventix FY18 report:

Set them against this from #FAB Fusion Antibodies' HY18 report today:

With FY17 results, Fusion was cut in half by guiding the disappearance of a fair whack of revenue. HY18 today shows it. They today guide to "modest" 18-19 growth.

Along with that revenue warning, news that a key customer collaboration agreement may not be renewed.

Results today have a new agreement with the customer as signed.

Further, this seems to have come out separately as well :

finance.yahoo.com/news/fusion-an…

They floated to do a big physical expansion of their labs and ramp up business. The former at least, has recently been achieved under budget.

It's Phil Fisher's kind of entry point: expansion happening during a period of turbulence.

Remember Abcam's failed bid for #HZD (CRISPR, rather than humanised antibodies)

Valueact continue to increase their stake. Sooner rather than later, that gets sold.

The failed bid validates #HZD's IP, their revenue further validates it and guides towards a much higher price.

None of this is present at #FAB (apart from turbulence) but bearing in mind the point from Bioventix at the start - you wouldn't necessarily expect it to be. This is what IP based long-term royalty businesses usually look like at this stage.

It's also what failures look like.

It's £13M. Their IP has produced decent, growing revenues very recently. They've got sunk costs in R&D, labs. They've got rare and specialised staff. They're picking themselves up.

I did say this was a stretch.

But for £13M, as a lottery ticket. I'll buy.

I've long since exited Fusion Antibodies #FAB - this just isn't going to work.

..that is, except however, if you're a director or key senior management of the company. In return for -53% HY1/19 revs & -19% FY19 FY revs: your pay increases by 22%.

Pat on the back lads.

Fusion Antibodies #FAB - possibly..

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling